Fulgent: 3 Key Takeaways for Long-Term Investors

Source The Motley Fool

Key Points

  • Fulgent expects full-year 2026 revenue of $330 million to $340 million.

  • Third-quarter cash reserves reached $652.4 million after a federal tax refund.

  • Laboratory AI slide image analysis volume grew 23% sequentially.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Fulgent (NASDAQ:FLGT) announced full-year 2026 revenue guidance of $330 million to $340 million. Cash reserves reached $652.4 million after the receipt of a federal tax refund, providing financial flexibility as laboratory collections recover. Three things management said stand out.

1. Billing Fixes Are Restoring Laboratory Collection Rates

Management transitioned its revenue cycle management (RCM), billing, and collection software to increase operational efficiency across newly acquired laboratories. Customization delays temporarily depressed collection rates in prior quarters, but operational adjustments delivered immediate sequential margin gains.

While this transition continued to have a negative impact on the third quarter, we are pleased to announce we have made significant progress and have seen a positive sequential trend in reimbursement which has contributed to improvements in our total revenue and gross margins as compared to the second quarter.
-- Brandon Perthuis, Chief Commercial Officer

2. Diagnostic Artificial Intelligence Integration Is Scaling Rapidly

Laboratory automation relies on artificial intelligence (AI, software designed to automate visual pattern recognition) to process tissue samples with high precision. Fulgent has scaled processing volume while reducing software analysis errors, thereby driving diagnostic speed and creating operational efficiency as test volumes grow.

During the third quarter, our AI platform analyzed approximately 255 thousand slide images representing a 23% increase from the second quarter. Importantly, as utilization has scaled, the technical reliability of the platform has improved substantially. With failed analysis declining to just 0.01% during the quarter.
-- Brandon Perthuis, Chief Commercial Officer

3. Targeted Oncology Platform Opens New Therapeutic Opportunities

Beyond diagnostic testing, Fulgent develops nanoencapsulated therapies designed to deliver cancer treatments directly to tumor cells while reducing side effects. Clinical development advanced for candidate FID-007 following a meeting with the Food and Drug Administration (FDA), moving the treatment closer to pivotal Phase 3 trials.

FID-007 is a nano-encapsulated peptide EXO developed under Fulgent's clean chemo platform. The platform is designed to reduce toxicity typically associated with conventional chemotherapy while maintaining or improving efficacy. A profile Fulgent delivery is preferable in combination oncology regimen.
-- Ming Hsieh, Chief Executive Officer

Looking Ahead

Operational momentum is building as billing software fixes take hold and clinical trials advance. Management prioritizes research and development (R&D) investments alongside sales integration, while monitoring reimbursement stability under the Protecting Access to Medicare Act (PAMA), a federal fee schedule framework.

We continue to prioritize our investment across 2 key areas: R&D, where we are advancing both our laboratory testing capabilities and clinical study pipeline and the integration of Bako Diagnostics and StrataDx where we are aligning our expanded sales organization, ... to drive productivity and operating efficiency.
-- Paul Kim, Chief Financial Officer

A cash balance of $652.4 million supports ongoing clinical drug development.

We believe we are well positioned for longer term growth and strategic investments, innovation and expanded offerings that deliver value.
-- Ming Hsieh, Chief Executive Officer

Should you buy stock in Fulgent Genetics right now?

Before you buy stock in Fulgent Genetics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Fulgent Genetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool has positions in and recommends Fulgent Genetics. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Nov 16, Mon
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Nov 16, Mon
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
23 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
1 hour ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
goTop
quote